NCT05205070Phase 2Status unknown
A Study to Evaluate the Efficacy and Safety of Rosnilimab (ANB030) in Treatment of Subjects With Moderate-to-Severe Alopecia Areata
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rosnilimab (ANB030) in the Treatment of Subjects With Alopecia Areata
In the register
The register attaches this trial to Rosnilimab (AnaptysBio), currently at “Discontinued” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Status unknown
- Declared phase
- Phase 2
- Sponsor
- AnaptysBio, Inc.
- Participants (registry)
- 45
- Start
- December 2021
- Primary completion
- January 2023
- Study completion
- March 2023
- Last registry update
- May 2022
- Countries
- United States
Conditions studied: Alopecia Areata
Interventions: Rosnilimab, ANB030, Placebo
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.